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Summary: For the Standardization of human plasma apolipoprotein A-I assay two well characterized mono-
clonal antibody mixtures were used to develop a sandwich immunoenzymometric assay. The monoclonal
antibody mixture l (A05-A17-A30) in solid phase technique was selected on the basis of its higher binding
capacity of [125I]HDL (41 ng per well) compared to polyclonal antibody (23 ng per well). The epitopes
recognized by monoclonal antibody mixture l are surface antigenic sites of apolipoprotein A-I expressed on
native HDL äs determined by competitive imhibition of labeled HDL. The peroxidase conjugated monoclonal
antibody mixture 2 (A03-A05-A17-A51) was selected on the basis of its ability to bind to apolipoprotein -
captured by monoclonal antibody mixture 1. For this, we used the 125I-labeled monoclonal antibodies.
Under optimized assay cönditioiis, the immunoenzymometric assay is precise (intra- and inter-assay coefficients
of variations 5.4% and 9.2% respectively). It yields plasma apolipoprotein A-I values that correlate highly
with those obtained with polyclonal antibody (r = 0.96). So the use of well characterized monoclonal antibody
mixtures reacting only to surface antigenic sites of apolipoprotein A-I present on native lipoprotein may
provide the possibility öf Standardization of apolipoprotein A-I measurement.
n o uc on , ^
 potential advantages of the enzymometric assay
Recently, numerous studies have demonstrated a de- are numerous: high sensitivity, specificity, flexibility
crease in apolipoprotein A-I in subjects with cpronary äs well äs no need for radioactive tracers. This assay
artery disease (1—6). Several techniques have been could be considered äs a possible reference method
used in the measurement ofcirculating apolipoprotein (12), but in the Standardization of apolipoprotein
A-I, including radial immunodiffusion (7), electroim- immunoassay careful attention must be paid not only
munoassay(8),radiQimmunoassay(9),iminunonephe- to the methodology, but also to the selection of an-
lometry (10) and more recently enzyme linked im- tibodies.
munoassay (ELISA) (11,12). Some examples of how plasma apolipoprotein A-I
.. · values vary with differing antisera have been reported
0 This work was suppprted-by Grant of CNAMTS - Inserm (13, 14); it is therefore particularly important that the
n° 86-3-42-7-E. antibodies used react with the same antigenic deter-
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minants at all times. Recommendations by the Work-
ing Group on Antibodies of the NIH Workshop on
Apolipoprotein Quantification outline the potential
interest of mixtures of monoclonal antibodies (15). In
this paper, we describe a sandwich enzymometric as-
say for human plasma apolipoprotein A-I using two
well selected mixtures of monoclonal antibodies for
both the immobilized and conjugated antibodies.
Materials and Methods
Plasma samples and lipoprotein Isolation
Human blood samples were obtained by venipuncture after an
overnight fast from "Centre de Medecine Preventive, Institut
Pasteur, Lilie". We also included in this study hyperlipidaemic
patients with triacylglycerol values greater than 1500 mg/1 and
cholesterol values greater than 2500 mg/1. Samples were col-
lected into tubes containing 0.5 ml of 5 mmol/1 EDTA and
centrifuged to eliminate cells. Total cholesterol and triacylgly-
cerols were measured in fresh plasma and apolipoprotein A-I
was always quantified within 48 h after addition of preservatives
s previously described (16).
Using Standard ultracentrifugation techniques, s described by
Havel et al. (17), we isolated HDL (d = 1.063-1.210 kg/l),
HDL2 (d = 1.063-1.100 kg/l) and HDL3 (d = 1.100-1.120
kg/l) from pooled fresh plasma. Apolipoprotein A-I was iso-
lated by "Fast Protein Liquid Chromatography" from HDL
apolipoproteins using a MonoQ Column (Pharmacia) and its
purity was conflrmed by SDS gels and amino acid analysis (18).
The purified protein served s immunogen for the production
of polyclonal antiserum.
Production and assessment of monoclonal antibod-
ies to apolipoprotein A-I
A male Balb/C mouse was immunized intraperitoneally on day
0 with 500 μg of HDL3 emulsified in 300 μΐ of complete Freund*
adjuvant and on day 21, with the same dose of HDL3, in
incomplete Freund* adjuvant. Two months later, at 10 days
before cell fusion, 300 μg of HDL3 in incomplete Freund*
adjuvant was administered intraperitoneally and 3 days prior
to fusion 300 μg of HDL3 was injected intraveno sly. We used
the HDL3 s immunogen since this major subfraction of the
HDL does not contain the Lp(a).
As described by Campbell (19), spieen cells were fused with
myeloma line SP2-O in the presence of polyethyleneglycol 1450
(Kodak) containing dimethylsulphoxide (Sigma), volume frac-
tion 0.1. The cells were distributed in microtiter plates. Hybri-
domas were screened for the secretion of specific antibodies by
ELISA (20) using microtiter plates coated with apolipoprotein
A-I or HDL3 and rabbit anti-mouse immunoglobulin conju-
gated with horseradish peroxidase (Nordic).
Positive wells were cloned twice by limiting dilution. Ascites
fluid was prepared by intraperitoneal injection of 2-4 · 106
hydridoma cells. Purification of antibodies was performed by
ammonium sulphate precipitation and affinity chromatography
on Protein A-Sepharose (Pharmacia).
In order to determine antibody specificity, immunoblotting was
performed s described by Towbin et al. (21). Apolipoprotems
from HDL were separated by SDS polyacrylamide gel electro-
phoresis, transfered to nitrocellulose and incubated with mono-
clonal antibody mixtures and polyclonal antibodies (15 mg/1)
diluted in Tris 15 mmol/1, NaCl 0.15 mol/1, Tween 0.5 ml/l, pH
8.0. Molecular weight Standards (Pharmacia) were used for
calibration. The bound antibodies were detected with peroxi-
dase-labeled rabbit anti-mouse and goat anti-rabbit immuno-
globulins.
Characterization of the monoclonal antibodies and
selection for the synthetic polyclonal
HDL were labeled with Na125I using iodihe monochloride (22).
The specific activity of the [J25I)HDL was 680 counts/min - ng
protein. Fourteen monoclonal antibodies were iodinated using
chloramine T (23). The specific activity ranged from 1250
counts/min · ng to 1610 counts/min · ng protein.
To assess the ability of labeled monoclonal antibodies to reveal
lipoprotein particles bound to an immobilized monoclonal an-
tibody, flexible microtiter plates (Falcon F3911) were coated
with one monoclonal antibody (A05, AI 7 pr A30) and 100 μΐ
of HDL ranging from 0.1 to 10 mg/1 was added and incubated
for 2 hours at 37 °C. After washing with phosphate b ffered
saline (containing NaCl 0.15 mol/1, pH 7.4), 100 μΐ of one 125I-
labelled monoclonal antibody (A03, A05, A17 or A51) con-
taining 100 000 counts/min was added and incubated for 2 hours
at 37 °C. The wells were washed with phosphate buffered saline,
cut and counted.
In order to study the binding and conipetitive displacement of
[125I]HDL, polystyrene microtiter plates (Costar 3590 USA)
were coated with 100 ul of a mixture of monoclonal antibodies
(mixture 1: A05-A17-A30, ratio 1:1:1) 15 mg/1 in phosphate
buffered saline overnight at room temperature, then blocked
by bovine sei um albumin 10 g/l for l hour. B vihe seruin
albumin 10 g/l was added to 100 μΐ of [125I]HDL (ranging from
0.5 to 5 mg/1 in phosphate buffered saline) and incubated for 2
hours at 37 °C. Competitive displacement of [125t]HDL was
investigated s follows: 50 μΐ of [125I]HDL at 7 mg/1 and 50 μΐ
of increasing amounts of competitors (pooled plasma, HDL or
pure apolipoprotein A-I ranging from 0.1 tp 100 mg/1) were
incubated for 2 hours. The free [12*I]HDL was aspirated and
counted in a gamma spectf ometer.
Immunoenzymometric assay
Monoclonal antibodies A03, A05, Al-7 and A51 were chpsen
for labeling for inclusion in the mixture of labeled monoclonal
antibodies. Each antibody (5 mg) was labeled separately with
horseradish peroxidase (2.5 mg) (Boehrjngef Mannheim, West
Germany) s previously described (16). Labeled antibodies were
stored at —20 °C with an equ l Volume of glycerol.
Polystyrene microtiter plates (Costar 3590) were coated for 16
hours at room temperature with 100 ul of monoclonal antibody
mixture l (A05—A17-A30, ratio l: l: 1) at 15 mg/1 in phos-
phate buffered saline. The wells were washed four times with
phosphate buffered saline. For the Standard curve, we used a
pool of plasma which had been calibrated s recommended by
Fesmire et al. (14).
Standards were diluted with phosphate buffered saline tp give
final concentrations of 10—150 μg/l apolipoprotein -I and
the plasma samples were diluted 15 000 and 25 O fold. Samples
or Standards (100 μΐ) were added to the wells and incubated at
37 °C for 2 hours. After washing, 100 μΐ of horseradish per-
oxidase-conjugated monoclonal antibody mixture 2 (A03+A05
A17 -h A51, ratio 1:1:1:1) diluted 15000-f ld in phosphate
bufTered saline-bovine serum albumin (10 g/l) were added arid
incubated 2 hours at 37 °C. After washing with phosphate
buffered saline, 100 μΐ of Substrate solution was added t the
wells. The Substrate was ^phenylene diamine (3 g/l in citf te-
phosphate 0.1 mol/1 pH 5.5 and concentrated H2O2 0.64 ml/l).
We allowed the colour tp develop at r om temperature f r 30
minutes and the reaction was stopped by 100 μΐ of l mol/1 HQ,
the bsorbance was read at 492 nm.
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Results
Characterization of monoclonal antibody
mixtures
From a single cell fusion, fourteen clones that secreted
anti-apolipoprotein A-I were selected. To develop the
immunoenzymometric assay, we selected a panel of
five monoclonal antibodies which recognized five in-
dividual epitopes of apolipoprotein A-I on the HDL
particles. The immobilized monoclonal antibody mix-
türe l (A05 — AI 7—A30) in solid-phase was used to
capture apolipoprotein A-I-containing lipoproteins in
plasma, and horseradish peroxidase-labeled mono-
clonal antibody mixture 2 (A03-A05-A17-A51)
was used to quantify the bound apolipoprotein A-I.
First, we determined the specificity of monoclonal
antibodies against apolipoprotein A-I-HDL by im-
munoblotting (fig. 1). In order to determine whether
antibodies become bound to different antigenic sites
on apolipoprotein A-I, the ability of each unlabeled
antibody to compete with the 125I-labeled antibody
for binding to apolipoprotein A-I was assessed. The
data (not shown) iiidicated that the antibodies A03,
A05, AI 7, A3Ö and A51 recognized different epitopes
of apolipoprotein A-I.
of the binding capacity was performed using 125I-
labeled HDL. The monoclonal antibody mixture l
(A05 —AI 7—A30) had a higher antigen binding ca-
pacity (41 ng HDL per well) than polyclonal antibody
(23 ng HDL per well) (fig. 2).
To determine the expression of the apolipoprotein -
epitopes recognized by the immobilized monoclonal
antibody mixture l, purified (delipidated) apolipopro-
tein A-I, HDL and plasma were studied for their
ability to displace 125I-labeled HDL in solid-phase.
Slope analysis of the logit-transformed competitive
curves (fig. 3) indicated that the epitopes recognized
S 2
Immobilized monoclonal antibody mixture l
To evaluate the capacity of the solid-phase mono-
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[125I]HDL bound [ng/welt]
clonal antibody to bind to HDL, Scatchard analysis
 pig 2 Scatchard plot
o—o mixture l of monoclonal antibodies: A05, AI 7,
A30
o—o polyclonal antiserum
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i
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Fig. 1. Western blots using different antibody preparations
1: HDL; Mixture of monoclonal antibodies A30, A05,
AI 7 against apolipoprotein A-I
2: HDL; Polyclonal antiserum against apolipoprotein
A-I
3: Siained electropherogram of purified apolipoprotein
A-I
4: Stained electropherogram of marker proteins for M\
estimation
CD
±: 0
-1
-2
0.1 1 10 100
c[mg/l]
Fig. 3. Competitive Inhibition of binding of [125I]HDL to im-
mobilized monoclonal antibody mixture 1: A05, AI 7,
A30 by
o-o HDL,
D — D apolipoprotein A-I and
o—o plasma.
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by the monoclonal antibody mixture l were similarly
expressed on isolated HDL and on native apolipo-
protein A-I-containing particles in the plasma. How-
ever, a difference in epitope expression was observed
for isolated apolipoprotein A-I. The polyclonal anti-
bodies, on the other band, recognized delipidated
apolipoprotein A-I äs well äs apolipoprotein A-I on
plasma HDL (fig. 4).
CD
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Fig. 4. Competitive Inhibition of binding of [125I]HDL to im-
mobilized polyclonal antibodies by
0-0 HDL
D — apolipoprotein A-I and
o—o plasma.
Labeled monoclonal antibody mixture 2
The monoclonal antibodies selected for the labeled
mixture 2 must be able to bind to apolipoprotein -
captured by the immobilized monoclonal antibody
mixture 1. We tested the ability of fourteen 125I-labeled
monoclonal antibodies to bind to apolipoprotein A-
I-HDL already captured by immobilized antibodies
A05, AI 7 and A30. Önly the labeled monoclonal
antibodies with high affinity apolipoprotein A-I bind-
ing are shown in figure 5. It is noted that the labeled
A05 and AI 7 bound weakly to apolipoprotein A-I
HDL captured by their respective non-labeled anti-
body. However, labeled A05 and AI 7 were able to
reveal apolipoprotein A-I bound to other antibodies.
Due to their high binding capacity monoclonal anti-
bodies A03 and A51 were included in the mixture 2.
Immunoenzymometric assay
Optimization of the method
With antibodies A05, AI 7 and A30 in an equimolar
ratio äs the solid-phase, we tested increasing concen-
trations of horseradish peroxidase-labeled mono-
clonal antibody mixture 2, which contained an equi-
molar ratio of labeled A03, A05, AI 7 and A51. Using
a 15000-fold dilütioii of mixture 2, we obtained a
Standard curve with the same slope and sensitivity äs
the polyclonal antibodies äs shown in figure 6 (12).
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Fig. 5. Capacity of labeled monoclonal antibodies used in the mixture 2 to bind to apolipoprotein A-I captured by immobitized
' monoclonal antibodies in solid-phase.
a) solid phase: AI 7
b) solid phase: A30
c) solid phase: A05
A03* etc = labeled monoclonal antibody
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Fig. 6. Standard curves for the quantitation of human apoli-
poprotein A-I in the plasma determined by polyclonal
antibodies (o) and monoclonal antibody raixtures (p).
The secondary Standard used for the comparison of the
curves was a frozen pool of different plasmas.
We note that monoclonal antibody mixtures could po-
tentially quantify more than the polyclonal antibodies
but the curve slopes were identical.
Comparative study of calibration curve with hyperli-
pidaemic plasmas
Using the immunoenzymometric method, we studied
the reaction curves of hypertriglyceridaemic, hyper-
cholesterolaemic and frozen plasrna, in order to com^
pare the slopes of the curves with thpse for normal
plasma (fig. 7 a and 7 b). We observed no modification
in the curve of these pathologic plasmas, indicating
that the recognition of the epitopes was identical in
all apolipoprotein A-I-containing particles.
Tab. 1. Intra- and inter-assay vari bility of the ELISA for
apolipoprotein A-I, using the monoclonal antibody.
Plasma Plasma Plasma Plasma
1 2 3 4
intfa-Assay
No. of determinations 33
Mean
SD
CV
g/l
g/i%
1.07
0.077
7.0
33
1.09
0.059
5.4
27
1.25
0.059
4.7
30
1.35
0.059
4.3
• Inter-assay
Mean
SD
CV
g/l
g/l%
1.08
0.088
8.1
1.10
0.094
8.5
1.38
0.112
8.1
1.39
0.167
12.1
102
Apolipoprotein A-I
103
i ^
102
Apolipoprotein A-I ίμς/l]
103
Fig. 7. Quantitative determination of human apolipoprotein
A-I in hypertriglyceridaemic (o), hypercholesterolaemic
(Δ), normal (D) and frozen (β) plasmas with monoclo-
nal antibodies (a) and polyclonal antibodies (b). What-
ever the concentration of apolipoprotein A-I in the
plasmas, the slopes of the curves were maintained de-
finitely parallel, although the curves themselves were
related tp the initial concentration of apolipoprotein
A-I.
Validation of ssays for plasma apolipoprotein A-I
The precision f the method was explored by meas-
uring the apolipoprotein A-I of four plasmas 27 to
33 times on the same plate to obtain the within assay
coefficient of Variation. These same four plasmas were
assayed on 5 different days to give the between assay
coefficient of Variation. The results, summarized in
table l, indicate that the experimental Variation of
the apolipoprotein A-I determination is similar when
performed with monoclonal antibody mixtures or
with the polyclonal antibody described previously.
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Tab. 2. EfTect of storage time and temperature on plasma apolipoprotein A-I.
Storage
Days:
Temperature
0: 20 °C
1: 4°C
7: 4°C
7: -20°C
7: -80°C
Mean
CV (%)
Plasma
1 2 3 4 5 6 7 8
Apolipoprotein A-I (g/l)
1.35
1.28
1.20
1.30
1.22
1.27
4.70
1.07
0.97
0.95
1.00
1.10
1.10
6.30
1.32
1.21
1.24
1.25
1.10
1.22
6.50
1.25
1.15
1.40
1.15
1.37
1.26
9.30
0.97
1.10
0.84
0.87
1.00
95
10.9
0.95
0.87
1.07
1.05
0.90
0.96
9.20
1.45
1.32 ' <
1.35
1.27
1.40
1.35
5.10
1.25
1.37
1.10
1.45
1.30
1.29
10.2
Effect of storage time and temperature on the plasma
apolipoprotein A-I determination
Because the immunoreactivity of one monoclonal an-
tibody against apolipoprotein A-I could change with
storage of serum at 4 °C (24), we investigated the
effect of storage and freezing on the plasma apoli-
poprotein A-I content. No significant changes in apo-
lipoprotein - determinations were registered when
the plasmas (n = 8) were stored at 4 °C, —20 °C or
-80°C(tab.2).
Correlation between apolipoprotein A-I concentrations
äs determined by our two immunoenzymometric ässays
The concentrations of apolipoprotein A-I in the
plasma, äs determined by immunoenzymoassay with
the monoclonal mixtures, correlate highly with the
concentrations of apolipoprotein A-I äs determined
in the polyclonal immunoenzymoassay. The correla-
r: 2
• *
2 *
11
• '
0 1 2
Apolipoprotein A-l (polydonal antisepumELISA) [g/l]
Fig. 8. Correlation between human apolipoprotein A4 concen-
trations äs determined by polyclonal antibodies
(m = 1.29 g/l) and monoclonal antibody inixtures
(m = 1.28 g/l) in sandwich ELISA. The equation of the
regression line is:
y = 1.035x - 0.045; r = 0.96 and n = 35
tion coefficient of 0.96 between these two immtmoen-
zymoassays was good. The equation of the regression
line was given in figure 8.
Disciission
Numerous epidemiologic studies have established the
role of human plasma apolipoprotein A-I in choles-
terol esterification and transport (25—28). Such a role
is consistent with apolipoprotein A-I äs a negative
risk factor for coronary artery disease.
The measurement of human plasma apolipoprotein
A-I is therefore of considerable clinical interest. How-
ever, despite efforts and an extensive literature, meas-
urement of this apolipoprotein has presented diffi-
culties. Measurements are influenced by the antigenic
site specificities of the antisera (13, 14), standardiza-
tion and the methodology employed in a particular
assay system. Consequently, there is the possibility of
considerable bias between laborätories or even within
the same laboratory during long-term studies.
The potential advantages of the immunoenzymome-
tric assay for apolipoprotein measurements have been
well documented (15, 16). The use of mixture of
monoclonal antibodies reacting only with surface an-
tigenic sites of apolipoprotein A-I expressed on native
high density lipoprotein particles may offer distinct
advantages with regard to standardization. These an-
tibodies not only confirin the specificity of the assay
system, but also ensure a constant source of unvarying
antibody.
Apolipoprotein A4 has been shown to contain dif-
ferent antigenic determinants (26, 27). In HDL par-
ticles, one segment is exposed or available to antibody,
whereas another segment appears to be masked by
lipids or other apolipoproteins (28). If the sample is
tested against polyclonal antibody with reactivity to
the unexposed determinants, the absolute arnount of
apolipoprotein A-I is underestimated. The sample is
theirefore often treated to maximizejmmunoassayable
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apolipoprotein A-I. Due to the fact that the mono-
clonal antibodies used in our assay are surface-specific
antibodies, such a treatment is not necessary and
apolipoprotein A-I present in all the density fractions
can be measured directly.
Thus, the use of a uniformly accepted reference Stand-
ard and of monoclonal antibodies in an immunoen-
zymometric assay permits Standardization of a
method, which could be of general use and suitable
for screening purposes.
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